PERSONALIZED MEDICINE - CHEMIST’S POINT OF VIEW



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The paper discusses the basic principles of personalized medicine and, first of all, the problems of the design of «personalized» drugs.

Full Text

Restricted Access

About the authors

L B Piotrovskiy

Institute of experimental medicine

Email: levon-piotrovsky@yandex.ru

References

  1. Ginsburg G.S., McCarthy J.J. Personalized medicine: Revolutionizing drug discovery and patient care // Trends in Biotechnology.- 2001.- Vol. 19 (12) - P. 491-496
  2. Пальцев М. Персонифицированная медицина // Наука в России.- 2011.- № 1.- C. 12-17.
  3. Zhang A., Sun H., Wang P., Han Y., Wang X. Future perspectives of personalized medicine intraditional Chinese medicine: A systems biology approach. // Complementary Therapies in Medicine.- 2012.- Vol. 20.- P. 93-99.
  4. Jain K.K. Personalized Medicine // Current Opin. Mol. Therap.- 2002.- Vol. 4 (6).- P. 548-558.
  5. Сычев Д.А., Антонов И.М., Загребин С.В. Алгоритмы дозирования варфарина, основанные на результатах фармакогенетического тестирования: реальная возможность оптимизации фармакотерапии // Рациональная фармакотерапия в кардиологии.- 2007.- Т. 3, № 2.- С. 59-66.
  6. Medawar P. The future of man // The Reith Lectures (BBC Radio 4, 1959).
  7. Pulendran B. Systems vaccinology: probing humanity’s diverse immune systems with vaccines // Proc. Natl. Acad. Sci. USA.- 2014.- Vol. 111.- P. 12300-12306.
  8. http://mkb-10.com/
  9. Баранов В.С., Баранова Е.В. Жить в гармониисо своими генами // Природа.- 2004.- № 12.- С. 3-9.
  10. Jergensen J.T. A challenging drug development process in the era of personalized medicine. // Drug Discovery Today.- 2011.- Vol. 16.- P. 891-897.
  11. Drews J. Strategic trends in the drug industry // Drug Discovery Today.- 2003.- Vol. 8 (9).- P. 411-420.
  12. Drews J., Ryser S. The role of innovation in drug development // Nat. Biotechnol.- 1997.- Vol.15.- P. 1318-1319.
  13. Pao W. A personal view on precision medicine.- 2016. Опубликовано онлайн: URL: www.roche.com (дата обращения 02.02.16).
  14. Marth J.D. A unified vision of the building blocks of life // Nature Cell Biology.- 2008.- Vol. 10 (9).- P. 1015-1016.
  15. Schork N.J. Time for one-person trials // Nature News.- 2015.- Vol. 520.- P. 609-611.
  16. Spear B.B., Heath-Chiozzi M., Huff J. Clinical application of pharmacogenetics // Trends Mol. Med.- 2001.- Vol. 7 (5).- P. 201-204.
  17. Freedman M.S. Treatment options for patients with multiple sclerosis who have a suboptimal response to interferon-β-therapy // Eur. J. Neurol.- 2014.- Vol. 21.- P. 377-387.
  18. Laupacis A., Sackett D.L., Roberts R.S. An assessment of clinically useful measures of the consequences of treatment // N. Engl. J. Med.- 1988.- Vol. 318 (26).- P. 1728-1733.
  19. https://www.whitehouse.gov/the-press-office/2015/01/30/fact-sheet-president-obama-s-precision-medicine-initiative.
  20. Toward precision medicine: building a new taxonomy of disease.- Washington, DC: National Academies Press, 2011.- 142 p.
  21. Ashley E.A. The precision medicine initiative: a new national effort // JAMA.- 2015.- Vol. 313 (21).- P. 2119-2120.
  22. Harries M., Smith I. The development and clinical use of trastuzumab (Herceptin) // Endocrine-Related Cancer.- 2002.- Vol. 9.- P. 7585.
  23. Tutt A., Robson M., Garber J.E. et. al. Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial // Lancet.- 2010.- Vol. 376 (9737).- P. 235-244.
  24. The case for personalized medicine.- 4th ed.- Personalized Medicine Coalition, 2014. Опубликовано онлайн: URL:http://www.personal-izedmedicinecoalition.org/Userfiles/PMCCorporate/file/pmc_the_case_for_personalized_medicine.pdf (дата обращения 02.02.16).
  25. Allison M. Is personalized medicine finally arriving? // Nat. Biotechnol.- 2008.- Vol. 26.- P. 509-517.
  26. Shin J., Kayser S.R., Langaee T.Y. Pharmacogenetics: from discovery to patient care // Am. J. Health Syst. Pharm.- 2009.- Vol. 66.- P. 625-637.
  27. Ikediobi O. N., Shin J., Nussbaum R. L. et al. UCSF Center for Translational and Policy Research on Personalized Medicine. Addressing the challenges of the clinical application of pharmacogenetic testing // Clin. Pharmacol. Ther.- 2009.- Vol. 86.- P. 28-31.
  28. Ginsburg G.S., McCarthy J.J. Personalized medicine: revolutionizing drug discovery and patient care // Trends Biotechnol.- 2001.- Vol. 19(12).- P. 491-496.
  29. Furka A., Sebestyen F., Asgedom M. et. al. General method for rapid synthesis of multicomponent peptide mixtures // Int. J. Peptide Protein Res.- 1991.- Vol. 37.- P. 487-493.
  30. Ahn B. C. Applications of molecular imaging in drug discovery and development process // Curr. Pharm. Biotechnol.- 2011.- Vol. 12 (4).- P. 459-468.
  31. Jorgensen J. T. Companion diagnostics: the key to personalized medicine // Expert Rev. Mol. Diagn.- 2015.- Vol. 15 (2).- P. 153-156.
  32. Ипатова О.М., Медведева Н.В., Арчаков А.И. и др. Трансляционная медицина - путь от фундаментальной биомедицинской науки в здравоохранение // Вестник РАМН.- 2012.- Т. 67, № 6.- С. 57-65.
  33. Jergensen J. T. Are we approaching the post-blockbuster era? Pharmacodiagnostics and rational drug development. // Expert Rev MolDiagn.- 2008.- Vol. 8 (6).- P. 689-695.
  34. Пиотровский Л. Б. Очерки о наномедицине.- СПб.: Росток, 2013.- 206 с.
  35. http://www.forbes.com/sites/henrymiller/2013/09/25/personalized-medicine-may-be-good-for-patients-but-bad-for-drug-companies-bot-tom-line/#68f6edc21d12
  36. Struewing J. P., Hartge P., Wacholder S. et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews // N. Engl. J. Med.- 1997.- Vol. 336 (20).- P. 1401-1408.
  37. Hood L. A. Personal View of Molecular Technology and How It Has Changed Biology // J. Proteome Res.- 2002.- Vol. 1 (5).- P. 399409.
  38. Weston A. D., Hood L. Systems biology, proteomics, and the future of health care: toward predictive, preventative, and personalized medicine // J. Proteome Res.- 2004.- Vol. 3.- P. 179-196.
  39. Sung N. S., Crowley W. F. Jr, Genel M. et. al. Central challenges facing the national clinical research enterprise // JAMA.- 2003.- Vol. 289 (10).- P. 1278-1287.
  40. Woolf S.H. The meaning of translational research and why it matters // JAMA.- 2008.- Vol. 299 (2).- P. 211-213.
  41. Аксенов В.А. Российская наномедицина: как выдать ситро за шампанское // Доказательная медицина и клиническая эпидемиология.- 2009.- № 2.- С. 38-42.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Piotrovskiy L.B.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 74760 от 29.12.2018 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies